Objective:To explore the influence of exercise rehabilitation training on cardiac function and prognosis in aged patients with coronary heart disease (CHD) and chronic heart failure (CHF) .Methods :A total of 82 aged CHD + CHF patients were randomly divided into routine treatment group (received CHF routine treatment ) and exercise rehabilitation group (received exercise rehabilitation training treatment based on routine treatment ) .Stroke volume (SV) ,left ventricular ejection fraction (LVEF) ,6min walking distance (6MWD) and NYHA cardiac func‐tion class were compared between two groups before and after treatment .Both groups were followed up for 12 months ,and CHF‐caused rehospitalization rate and cardiogenic mortality were compared between two groups .Re‐sults:Before treatment ,there were no significant difference in SV ,LVEF ,6MWD and NYHA cardiac function class between two groups ( P>0.05) .Compared with before treatment ,SV ,LVEF and 6MWD significantly rose and NYHA cardiac function class significantly reduced after treatment in both groups , P<0.01 all .Compared with routine treatment group ,there were significant rise in SV [ (50.8 ± 5.9) ml vs .(58.6 ± 6.2) ml] ,LVEF [ (44.9 ± 6.7)% vs .(50.2 ± 7.2)% ] and 6MWD [(139.7 ± 18.9) m vs .(175.2 ± 21.4) m] ,and significant reduction in NY‐HA cardiac function class [ (2.1 ± 0.5) classes vs .(1.7 ± 0.6) classes] after treatment in exercise rehabilitation group , P<0.01 all .Within 12‐month follow up ,CHF‐caused rehospitalization rate in exercise rehabilitation group was significantly lower than that of routine treatment group (9.8% vs .26.8% ) , P<0.05. Conclusion:Exercise re‐habilitation training can improve cardiac function ,exercise capacity and prognosis in aged CHD + CHF patients , which is worth clinical extending and applicating .

Objective To investigate the biological characteritics of adult animal hepatocytes induced by phenobarbital sodium(PBS) in vivo,and to study the potential value of biological artificial liver of effective hepatocytes.Methods 12 adult male mice,are yandomly divided in to preinducing group and controll group.The preinducing group are intraperitoneally injected PBS per day,45mg/kg for 7 times in total;the controll ware injected NS.after that,we detected the blood serum TP,BUN,CHOL,HDLC.And the same amount of isolative hepatocytes was developed after being developed 48h;MTT was used to investigate the proliferation of hepatocytes after being developed 24h;chromosome was investigated to observe the cell division;and the survival deadline and morphology was also investigated.Results The TP had remarkable difference between the two groups(t=2.678,P

Objective The aim of this study was to evaluate the benefits of i.v. iron therapy in iron-defi-cient patients with left ventricular ejection fraction preserved heart failure (HFpEF). Methods 61 HFpEF pa-tients with iron deficiency were randomized to treatment with or without i.v. iron,as ferric carboxymaltose(FCM, n = 31)or placebo(saline,n = 29)for 24 weeks of a double-blind,placebo-controlled trial. The primary end-point was the change in 6-min-walk-test(6MWT)distance from baseline to Week 24. Secondary end-points includ-ed changes in New York Heart Association(NYHA)class,health-related quality of life(QoL),with NT-proBNP under observation. Results Compared with the control group at week 16 and 24,the iron treatment group has much more improve in 6MWT and the health-related quality of life(HRQoL)(P<0.05). The changes in NT-proB-NP level and NYHA heart function classification only show significance at week 24(P<0.05)but not at week 16 (P>0.05). Conclusion In this study,Treatment with intravenous ferric carboxymaltose can improve symptoms, functional capacity,and quality of life.